GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Research & Development

Regenicin (Regenicin) Research & Development : $0.10 Mil (TTM As of Mar. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Regenicin Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Regenicin's Research & Development for the three months ended in Mar. 2023 was $0.10 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2023 was $0.10 Mil.

Regenicin Research & Development Historical Data

The historical data trend for Regenicin's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Research & Development Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.10

Regenicin Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenicin  (OTCPK:RGIN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Regenicin Research & Development Related Terms

Thank you for viewing the detailed overview of Regenicin's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenicin (Regenicin) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Research & Development
Comparable Companies
NOVNQ TMBRQ RGRX PCNT NMTRQ ONCSQ QBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY XBRU:ARGX OCSE:GMAB SZSE:300122
Traded in Other Exchanges
N/A
Address
10 High Court, Little Falls, NJ, USA, 07424
Website
https://www.regenicin.com
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines